Dose-response effects of zaleplon as compared with triazolam (0·25 mg) and placebo in chronic primary insomnia

Human Psychopharmacology

Volumn 15, Issue 8, 2000, Pages 595-604

  Drake, Christopher L ^a   Roehrs, Timothy A ^a   Mangano, Richard M ^b   Roth, Thomas ^b  

^a HENRY FORD HOSPITAL   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Cognitive performance; Hypnotics; Insomnia; Sleep; Triazolam; Zaleplon

Indexed keywords

PLACEBO; TRIAZOLAM; ZALEPLON;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; SEDATION; SLEEP PARAMETERS; TASK PERFORMANCE;

EID: 0034491443     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.216     Document Type: Article

References (35)

1. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers
2. Effects of a single dose of flurazepam on the sleep of healthy volunteers
3. Characteristics of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. I
4. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic
5. A dose response study of the hypnotic effectiveness of alprazolam and diazepam in normal subjects
6. Zolpidem-polysomnographic study of the effect of a new hypnotic drug in sleep apnea syndrome
7. Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: An overview of insomnias and related disorders - Recognition, epidemiology, and rational management
8. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening
9. Daytime alertness, insomnia, and benzodiazepines
10. Zaleplon: Dose-response evaluation in primary insomnia
11. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic
12. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?
13. Cognitive deficits in insomnia patients
14. Dose-related effects of flurazepam on human sleep-walking patterns
15. Management of insomnia
16. Sleep problems and their correlates in a working population
17. Daytime residual effects and motor activity after three benzodiazepine hypnotics
18. Nonselective and selective benzodiazepine receptor agonists - Where are we today?
19. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy
20. Sedative, memory, and performance effects of hypnotics
21. Zaleplon pharmacokinetics and absolute bioavailability
22. Dynamic consequences and correlates of insomnia in the United States: Results of the 1991 National Foundation Survey. II
23. The differential effects of short- and long-acting benzodiazepines upon nocturnal sleep and daytime performance
24. Effects of temazepam, flurazepam and quinalbarbitone on sleep: Psychomotor and cognitive function
25. Sedative effects of antihistamines
26. Zolpidem in the treatment of transient insomnia: A double-blind, randomized comparison with placebo
27. A review of the safety profiles of benzodiazepine hypnotics
28. Pharmacology and hypnotic efficacy of triazolam
29. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia
30. Prevalence, burden, and treatment of insomnia in primary care
31. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia
32. The morbidity of insomnia uncomplicated by psychiatric disorders